

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health products and supplements, with a focus on plant-based extracts including medicinal cannabis.

CAPITAL STRUCTURE

ASX code **BDA**
 Shares on issue 69.4m
 Market Capitalisation ~\$30m

BOARD & MANAGEMENT

Mr George Livery
 Executive Chairman

Ms Jo Patterson
 Chief Executive Officer

Mr Stephen Thompson
 Executive Director

Mr Simon O'Loughlin
 Non-Executive Director

Mr Simon Taylor
 Non-Executive Director

Mr Stephen Kelly
 Company Secretary

CONTACT

Level 1, 377 New South Head Rd
 Double Bay, NSW 2028

T +612 9199 5018
 E info@bodaustralia.com.au

Bod progresses European expansion following LOI with Tilman S.A.

- **Tilman to distribute Bod's cannabis products in Belgium and Luxemburg – additional countries in the EU to also be considered**
- **Tilman are a leading natural medicines manufacturer with an established distribution network – LOI extends the longstanding relationship between the two parties**
- **Agreement provides Bod with the ability to leverage Tilman's relationships with large pharmacy groups and specialty retailers, de-risking market entry**
- **First sales expected in the near term following local regulatory confirmation – Bod is also progressing similar agreements with major counterparties in the region**

Sydney, Australia – 11 March 2019: Developer and distributor of natural, evidence-based skincare and health products with a focus on medicinal cannabis, Bod Australia Limited ("Bod", the "Company") (ASX: BDA) advises it has executed a letter of intent (LOI) with longstanding partner and Belgian based natural medicine manufacturer, Tilman S.A. ("Tilman").

Under the agreement, Tilman will distribute Bod's cannabis ranges, NutraCabilis and MediCabilis, to its established network of pharmacies and specialty retailers in Belgium and Luxemburg.

In addition to the LOI, Bod has also extended its exclusive distribution rights of Tilman's products in Australia, New Zealand and China (e-commerce) to include five new ranges. New ranges include: SediStress, Enterofytol, Nasafytol, Antemetil and Tensifytol. Bod is confident that these new products will add to the Company's growing sales profile in the near term.

Tilman is a leading, Belgium-based, natural medicines manufacturer and a longstanding partner of the Company (refer ASX announcement: 12 December 2016). Tilman has over 60 years experience and combine quality management, extensive research and development and international commercial acumen to deliver yearly sales in excess of €35m.

Belgium is a potentially lucrative market for Bod's products, with favourable pharmaceutical and medicinal cannabis regulation already in place. Further, the country spends over €43.9Bn on healthcare and €1.72Bn on total beauty and wellbeing annually.

Board and management are confident that Tilman will assist in driving product uptake and sales growth throughout Europe following the approvals from local authorities. Further, Bod advises it is progressing similar agreements across Europe with major counterparties as part of its international expansion objectives.

Bod Australia CEO Jo Patterson said: "This agreement with Tilman marks the beginning of Bod's rapid expansion into Europe.

"Tilman and Bod have a longstanding relationship and the Company is pleased to be able to progress this, in what could be a very positive agreement for both parties. Tilman will provide Bod with an established distribution network and the expertise to drive product uptake and increase sales across Belgium and Luxemburg initially.

"Bod has also progressed discussions with other significant counterparties in the region to drive distribution and expansion. Board and management look forward to updating shareholders as additional agreements are secured."

- ENDS -

ABOUT BOD AUSTRALIA

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health and skincare products. Bod works with plant based extracts, with specific expertise in leveraging the health benefits associated with cannabis and hemp.

Bod is rapidly building an integrated cannabis business, underpinned by agreements with international counterparties Linnea SA, a leading Swiss botanicals extracts manufacturer and iX Biopharma Limited, a late stage Singapore-listed pharmaceutical company. Bod is actively developing a range of over-the-counter and prescription products based on its unique, standardised, pharmaceutical grade cannabis extracts.

The Company has a large distribution footprint in Australia, selling prescription and OTC products to over 1,000 retail outlets, including pharmacies, retail stores and healthcare chains. The Company also has distribution agreements with two of Australia's largest pharmacy wholesalers providing it with access to over two thirds of the market. Bod is also actively building capability in key European markets that it witnesses near term growth prospects.

For more information please contact:

Jo Patterson
Chief Executive Officer
info@bodaustralia.com
+61 2 9199 5018

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 431 271 538

use only
For personal

